Two Boston-based researchers shared methods for detecting circulating nucleic acid biomarkers for potential use in cancer diagnosis and monitoring.
In Phase II testing, the company has shown that an epigenetic biomarker associated with the drug's target can predict patients' responses to treatment.
The method, developed by scientists at Uppsala University in Sweden, uses antibody-based proximity assays alongside off-the-shelf gene expression assays.
Through comprehensive genomic profiling, researchers identified molecular events that cause lower grade gliomas to progress to more deadly forms of brain cancer.
In PLOS this week: genetic diversity of Theileria annulata parasite, gene expression patterns in glioblastoma, and more.
An Institute of Cancer Research-led team conducted a meta-analysis that uncovered five new variants linked to glioma development, including one that greatly increases risk of glioblastoma.
The unique stem cells may be the key to understanding how the primate brain grew and expanded during evolution.
Paradigm will use its NGS-based PCDx panel to characterize patient tissue samples in a phase I clinical study of altiratinib.
The CDx test will be developed to identify best responders for Apogenix's APG101 for treating solid tumors and malignant hematological diseases.
The funds will support work to evaluate the effectiveness of the company's immunosignature technology in the diagnosis of brain cancer.
The Guardian reports that the Mammalian Genetics Unit at the Harwell Institute is to close.
Scientific research itself contributes to plastic waste and isn't very sustainable, FiveThirtyEight reports.
Restaurants in the US may soon serve AquaBounty's genetically modified salmon, according to the Associated Press.
In Science this week: three studies from the Ruminant Genome Project, and more.